Literature DB >> 24456621

Addicted to secrete - novel concepts and targets in cancer therapy.

Nicolas Dejeans1, Serge Manié2, Claudio Hetz3, Frédéric Bard4, Ted Hupp5, Patrizia Agostinis6, Afshin Samali7, Eric Chevet8.   

Abstract

The unfolded protein response (UPR) mediates the adaptation of the secretory pathway (SP) to fluctuations in cellular protein demand or to environmental variations. Recently, drug screenings have confirmed the therapeutic potential of targeting the UPR in cancer models. However, the UPR may not be the only druggable target of the SP. Moreover, recent studies have revealed other contributions of the SP to cancer development. This article does not intend to describe the well-established implication of UPR signaling pathways in cancer cell life and cell decision, but rather aims at defining the concept of 'tumor cell secretory addiction', from molecular, cellular, and therapeutic perspectives. Furthermore, the implication of UPR modulations in this context will be discussed.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cancer therapy; secretory pathway; unfolded protein response

Mesh:

Substances:

Year:  2014        PMID: 24456621     DOI: 10.1016/j.molmed.2013.12.003

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  25 in total

Review 1.  Endoplasmic reticulum proteostasis: a key checkpoint in cancer.

Authors:  Scott A Oakes
Journal:  Am J Physiol Cell Physiol       Date:  2016-11-16       Impact factor: 4.249

Review 2.  Natural products as modulators of eukaryotic protein secretion.

Authors:  Hendrik Luesch; Ville O Paavilainen
Journal:  Nat Prod Rep       Date:  2020-02-18       Impact factor: 13.423

Review 3.  Endoplasmic Reticulum Stress Signaling in Cancer Cells.

Authors:  Scott A Oakes
Journal:  Am J Pathol       Date:  2020-02-27       Impact factor: 4.307

4.  Integrative quantitative proteomics unveils proteostasis imbalance in human hepatocellular carcinoma developed on nonfibrotic livers.

Authors:  Luc Negroni; Said Taouji; Daniela Arma; Nestor Pallares-Lupon; Kristen Leong; Lee Anne Beausang; Martin Latterich; Roger Bossé; Charles Balabaud; Jean-Marie Schmitter; Paulette Bioulac-Sage; Jessica Zucman-Rossi; Jean Rosenbaum; Eric Chevet
Journal:  Mol Cell Proteomics       Date:  2014-09-15       Impact factor: 5.911

Review 5.  TMBIM protein family: ancestral regulators of cell death.

Authors:  D Rojas-Rivera; C Hetz
Journal:  Oncogene       Date:  2014-02-24       Impact factor: 8.756

6.  Golgi phosphoprotein 2 (GOLPH2) is a novel bile acid-responsive modulator of oesophageal cell migration and invasion.

Authors:  Anne-Marie Byrne; Spiros Bekiaris; Gina Duggan; David Prichard; Murat Kirca; Stephen Finn; John V Reynolds; Dermot Kelleher; Aideen Long
Journal:  Br J Cancer       Date:  2015-10-13       Impact factor: 7.640

Review 7.  Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress.

Authors:  Abhishek D Garg; Hannelore Maes; Alexander R van Vliet; Patrizia Agostinis
Journal:  Mol Cell Oncol       Date:  2014-12-01

8.  Netrin-1 Protects Hepatocytes Against Cell Death Through Sustained Translation During the Unfolded Protein Response.

Authors:  Thomas Lahlali; Marie-Laure Plissonnier; Cristina Romero-López; Maud Michelet; Benjamin Ducarouge; Alfredo Berzal-Herranz; Fabien Zoulim; Patrick Mehlen; Romain Parent
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2016-01-09

9.  miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.

Authors:  Yuan Wang; Rachel Lieberman; Jing Pan; Qi Zhang; Meijun Du; Peng Zhang; Marja Nevalainen; Manish Kohli; Niraj K Shenoy; Hui Meng; Ming You; Liang Wang
Journal:  Mol Cancer       Date:  2016-11-10       Impact factor: 27.401

10.  Unconjugated secondary bile acids activate the unfolded protein response and induce golgi fragmentation via a src-kinase-dependant mechanism.

Authors:  Ruchika Sharma; Francis Quilty; John F Gilmer; Aideen Long; Anne-Marie Byrne
Journal:  Oncotarget       Date:  2017-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.